Get the Stockscreener App
1.49
0.00%
0.00
After Hours:
1.50
0.01
+0.67%
Neuronetics Inc stock is traded at $1.49, with a volume of 172.87K.
It is up +0.00% in the last 24 hours and up +29.57% over the past month.
Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.
See More
Previous Close:
$1.49
Open:
$1.48
24h Volume:
172.87K
Relative Volume:
0.43
Market Cap:
$82.92M
Revenue:
$69.23M
Net Income/Loss:
$-33.10M
P/E Ratio:
-1.2627
EPS:
-1.18
Net Cash Flow:
$-39.26M
1W Performance:
+0.68%
1M Performance:
+29.57%
6M Performance:
-16.29%
1Y Performance:
-44.40%
1-Day Range:
$1.4461
$1.53
1-Week Range:
$1.40
$1.66
52-Week Range:
$0.52
$5.0699
Neuronetics Inc Stock (STIM) Company Profile
Name
Neuronetics Inc
Sector
Industry
Phone
877-600-7555
Address
3222 PHOENIXVILLE PIKE, MALVERN, PA
Compare STIM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
STIM
Neuronetics Inc
|
1.49 | 82.92M | 69.23M | -33.10M | -39.26M | -1.18 |
|
TMO
Thermo Fisher Scientific Inc
|
532.02 | 203.50B | 42.37B | 6.14B | 7.78B | 15.95 |
|
DHR
Danaher Corp
|
234.84 | 169.62B | 23.74B | 3.89B | 4.98B | 5.24 |
|
A
Agilent Technologies Inc
|
135.69 | 38.75B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IQV
Iqvia Holdings Inc
|
197.39 | 35.83B | 15.32B | 1.41B | 1.96B | 7.62 |
|
IDXX
Idexx Laboratories Inc
|
415.53 | 34.03B | 3.84B | 866.24M | 792.60M | 10.37 |
Neuronetics Inc Stock (STIM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-13-21 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-13-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-22-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Feb-06-20 | Initiated | BTIG Research | Buy |
| Jul-24-18 | Initiated | Canaccord Genuity | Buy |
View All
Neuronetics Inc Stock (STIM) Latest News
Neuronetics Awards Stock Units to New Employee Bill Leonard - MSN
Neuronetics (NASDAQ:STIM) Is Making Moderate Use Of Debt - Simply Wall St
HighTower Advisors LLC Increases Stock Holdings in Neuronetics, Inc. (NASDAQ:STIM) - Defense World
Neuronetics (STU:NRC) Future 3-5Y EPS without NRI Growth Ra - GuruFocus.com
Neuronetics Revamps TrakStar System, Streamlining Patient Data Management - MSN
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Neuronetics Grants Strategic 50,000 PRSU Inducement Award to Key New Employee - StockTitan
Neuronetics' SWOT analysis: merger impact on neurohealth stock By Investing.com - Investing.com Australia
Neuronetics Unveils Strategic Performance-Based Stock Awards Targeting Cash Flow Breakeven by 2025 - StockTitan
Neuronetics' SWOT analysis: merger impact on neurohealth stock - Investing.com
Neuronetics, Greenbrook TMS close transaction - Medical Buyer
Neuronetics Expands with Greenbrook TMS Acquisition - TipRanks
Madryn Provides Update on Holdings of Greenbrook TMS Inc. - The Manila Times
Neuronetics and Greenbrook TMS Announce Closing of Transaction - The Manila Times
Reviewing Stryker (NYSE:SYK) & Neuronetics (NASDAQ:STIM) - Defense World
Neuronetics' SWOT analysis: merger, market challenges shape TMS stock outlook - Investing.com Nigeria
Neuronetics (STU:NRC) 3-Year EPS without NRI Growth Rate : 9.40% (As of Sep. 2024) - GuruFocus.com
Neuronetics (STU:NRC) Profitability Rank : 1 (As of Sep. 2024) - GuruFocus.com
Greenbrook TMS Q3 Revenue Up 9% to $18.9M, Plans to Close 23 Centers Amid Merger - StockTitan
Transcranial Magnetic Stimulator Market Overall Study Report - openPR
GSA Capital Partners LLP Purchases 30,837 Shares of Neuronetics, Inc. (NASDAQ:STIM) - Defense World
Transcranial Magnetic Stimulator Market Future Business - openPR
FDA Clears NeuroStar's TMS Therapy for Adolescents with Major Depressive Disorder - MSN
Neuronetics to Showcase Neurohealth Innovations at Piper Sandler Healthcare Conference! - MSN
Greenbrook TMS Strategic Acquisition and Restructuring by Neuronetics - TipRanks
Neuronetics Announces Q3 2024 Financial Results and Greenbrook TMS Acquisition Approval - MSN
Neuronetics to Present at the Piper Sandler 36th Annual Healthcare Conference - The Manila Times
Neuronetics to Present at Piper Sandler Healthcare Conference in December 2024 | STIM Stock News - StockTitan
Neuronetics Grants Inducement Awards to New Employees - MSN
Neuronetics Expands TMS Coverage, Enhancing Access for MDD Treatment - MSN
Neuronetics, Inc. (NASDAQ:STIM) Analysts Just Slashed Next Year's Revenue Estimates By 12% - Simply Wall St
Neuronetics Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Need To Know: The Consensus Just Cut Its Neuronetics, Inc. (NASDAQ:STIM) Estimates For 2025 - Yahoo Finance
William Blair Decreases Earnings Estimates for Neuronetics - Defense World
Greenbrook TMS Acquisition by Neuronetics Approved - TipRanks
Neuronetics, Inc. (NASDAQ:STIM) Analysts Are Cutting Their Estimates: Here's What You Need To Know - Yahoo Finance
Neuronetics regains Nasdaq compliance with bid price By Investing.com - Investing.com Australia
CANNELL CAPITAL LLC Adjusts Stake in Neuronetics Inc - GuruFocus.com
Neuronetics Inc. (STIM) Quarterly 10-Q Report - Quartzy
Earnings call: Neuronetics reports revenue growth amidst strategic shifts By Investing.com - Investing.com Australia
Neuronetics (STIM) Reports Q3 Loss, Lags Revenue Estimates - MSN
Neuronetics regains Nasdaq compliance with bid price - Investing.com
Earnings call: Neuronetics reports revenue growth amidst strategic shifts - Investing.com
Neuronetics, Inc. (NASDAQ:STIM) Q3 2024 Earnings Call Transcript - Insider Monkey
Neuronetics announces inducement grant - Medical Buyer
Neuronetics Inc Stock (STIM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Neuronetics Inc Stock (STIM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MACAN WILLIAM ANDREW | EVP, GC, CCO and CS |
Oct 08 '24 |
Sale |
0.82 |
1,541 |
1,264 |
402,792 |
0.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):